Norges Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
|
|||||
|
2025
Q2 | $663M | Buy |
|
|||||
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $578M | Buy |
|
|||||
|
2024
Q3 | $653M | Buy |
|
|||||
|
2024
Q2 | $558M | Buy |
|
|||||
|
2024
Q1 | $343M | Buy |
|
|||||
|
2023
Q4 | $390M | Buy |
|
|||||
|
2023
Q3 | $211M | Buy |
|
|||||
|
2023
Q2 | $134M | Sell |
|
|||||
|
2023
Q1 | $305M | Buy |
|
|||||
|
2022
Q4 | $241M | Sell |
|
|||||
|
2022
Q3 | $244M | Sell |
|
|||||
|
2022
Q2 | $187M | Sell |
|
|||||
|
2022
Q1 | $211M | Buy |
|
|||||
|
2021
Q4 | $215M | Buy |
|
|||||
|
2021
Q3 | $188M | Buy |
|
|||||
|
2021
Q2 | $152M | Sell |
|
|||||
|
2021
Q1 | $136M | Sell |
|
|||||
|
2020
Q4 | $135M | Sell |
|
|||||
|
2020
Q3 | $151M | Buy |
|
|||||
|
2020
Q2 | $134M | Sell |
|
|||||
|
2020
Q1 | $108M | Sell |
|
|||||
|
2019
Q4 | $116M | Sell |
|
|||||
|
2019
Q3 | $90.4M | Sell |
|
|||||
|
2019
Q2 | $82.6M | Sell |
|
|||||
|
2019
Q1 | $107M | Sell |
|
|||||
|
2018
Q4 | $94.2M | Buy |
|
|||||
|
2018
Q3 | $99.2M | Buy |
|
|||||
|
2018
Q2 | $80.6M | Buy |
|
|||||
|
2018
Q1 | $95.8M | Buy |
|
|||||
|
2017
Q4 | $94.3M | Buy |
|
|||||
|
2017
Q3 | $65.2M | Sell |
|
|||||
|
2017
Q2 | $59.4M | Buy |
|
|||||
|
2017
Q1 | $33M | Sell |
|
|||||
|
2016
Q4 | $24.9M | Buy |
|
|||||
|
2016
Q3 | $35.5M | Buy |
|
|||||
|
2016
Q2 | $25.6M | Buy |
|
|||||
|
2016
Q1 | $27M | Sell |
|
|||||
|
2015
Q4 | $56.3M | Sell |
|
|||||
|
2015
Q3 | $53.4M | Buy |
|
|||||
|
2015
Q2 | $68.8M | Sell |
|
|||||
|
2015
Q1 | $62.2M | Buy |
|
|||||
|
2014
Q4 | $53.6M | Buy |
|
|||||
|
2014
Q3 | $39.7M | Sell |
|
|||||
|
2014
Q2 | $64.2M | Buy |
|
|||||
|
2014
Q1 | $26.4M | Hold |
|
|||||
|
2013
Q4 | $25.3M | Buy |
|
|||||
|
2013
Q3 | $24.2M | Buy |
|
|||||
|
2013
Q2 | $9.81M | Buy |
|